At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 25 enrolled

Drug / intervention

Fluoxetine +1 moredrug

Likely dose

Fluoxetine 10 mgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00296725

NCT00296725Phase 2Completed

Compare CT.gov

Dichotic Listening as a Predictor of Placebo and Medication Response in Depression

New York State Psychiatric Institute·interventional·Posted Feb 27, 2006·Updated May 30, 2019

In Brief

A Phase 2 clinical trial evaluating Fluoxetine and Imipramine for Major Depression and 2 related conditions. Completed, enrolled 25 participants across 1 site.

Detailed Summary

Depressed patients will have hearing tests and then be treated with up to three treatments (i.e., Fluoxetine, Imipramine) until remitted, to see whether test results predict specific outcomes.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsMajor Depression, Dysthymia, Depressive Disorder Not Otherwise Specified

CountriesUnited States

Collaborators--

Timeline

Phase 2CompletedFinished

1994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Enrollment StartApr 1994

First PostedFeb 2006

Primary CompletionJun 2011

TodayJul 2026

First PostedFeb 27, 2006

Enrollment StartApr 1, 1994

Primary CompletionJun 1, 2011

TodayJul 2, 2026

Enrollment to primary: 17.2 yearsPosted 20.3 years ago

Interventions

Fluoxetinedrug

Phase 1: Fluoxetine: wk 1: 10 mg/day; wks 2-3: 20 mg/day; wks 4-5: 40 mg/day; wk 6: 60 mg/day; wks 7-12: 80 mg/day \*All increases only if tolerated.

Imipraminedrug

Phase 2: Imipramine wk 1: 25 mg/day; wk 2: 50 mg/day; wk 3: 100 mg/day, 150 mg/day after 3 days; wk 4: 200 mg/day, 250 mg/day after 3 days; wks 5-6: 300 mg/day. \*All increases only if tolerated.